🌸 The Female Wellness Revolution

📑 Table of Contents

1. The Midlife Shift: Understanding Perimenopause and Menopause
2. Hormone Replacement Therapy (HRT): The Gold Standard
   • Benefits and Risks by Age
   • The Estrogen-Progesterone-Testosterone Trio
3. The Testosterone-Libido Connection
   • HSDD and the Evidence for Testosterone
   • The “Conundrum”: Libido Highs and Hair Loss Lows
4. Peptide Therapy: The New Frontier
   • BPC-157: The Healing Peptide
   • TB-500: The Regenerative Peptide
   • GHK-Cu: The Copper Peptide for Skin and Tissue
   • CJC-1295 & Ipamorelin: Growth Hormone Secretagogues
   • Collagen Peptides for Genitourinary Health
   • ProGo®: Salmon Protein Hydrolysate for Metabolic Health
   • Oral Peptides for Bone Health (EB613)
5. The Foundation First: A Cautious, Evidence-Based Approach
6. FAQ Section
7. References and Further Reading
8. Disclaimer
9. PS

1. The Midlife Shift: Understanding Perimenopause and Menopause

The menopausal transition is a profound biological shift that affects virtually every system in a woman’s body. It is not merely the end of fertility; it is a fundamental hormonal realignment that can impact mood, energy, cognition, sleep, body composition, and sexual health. The average woman experiences 7 to 10 concurrent symptoms across psychological, cognitive, pain, and sleep domains during this transition, which can substantially impair quality of life. These symptoms, including hot flashes, night sweats, weight gain, brain fog, and musculoskeletal pain, are driven by the fluctuating and ultimately declining levels of ovarian hormones—primarily estrogen and progesterone.

For years, the narrative around these symptoms was one of silent suffering. However, the conversation has shifted dramatically. Women are now empowered to seek solutions, and the medical community is increasingly focused on providing evidence-based care to navigate this natural but often disruptive life stage.

2. Hormone Replacement Therapy (HRT): The Gold Standard

Hormone Replacement Therapy (HRT) remains the most rigorously studied and effective treatment for managing the troublesome symptoms of menopause. Current guidelines recommend HRT for perimenopausal and early postmenopausal women without contraindications who are experiencing significant vasomotor symptoms (hot flashes, night sweats). The benefits and risks of HRT are heavily influenced by a woman’s age and time since menopause onset.

Benefits and Risks by Age

A key framework for understanding HRT risk is the “timing hypothesis,” which suggests that the benefits of HRT are most pronounced when it is initiated close to the onset of menopause.

• Women <50 years: For women experiencing menopausal symptoms under 50, HRT should be offered, as the benefits far outweigh the risks.
• Women 50–60 years: For women between 50 and 60, the benefits of HRT continue to outweigh the risks, with studies showing potential additional benefits like a reduction in overall mortality and coronary artery disease.
• Women >60 years: For women over 60, the benefits of HRT are more balanced with the risks, and treatment should be individualized based on a woman’s health profile and risk factors.
• Women >70 years: By age 70, the risks tend to outweigh the benefits for most women.

While HRT is highly effective for vasomotor symptoms and genitourinary syndrome of menopause (GSM), it may also offer secondary benefits for mood, libido, and fracture prevention. However, these are not considered primary indications for treatment. For vaginal symptoms alone, local (vaginal) estrogen is often sufficient and carries minimal systemic risk.

The Estrogen-Progesterone-Testosterone Trio

While estrogen is the primary focus of HRT, it is rarely prescribed alone for women with an intact uterus due to the risk of endometrial cancer. Progesterone (or a progestin) is added to protect the uterine lining. Beyond these, a third key hormone is gaining significant attention: testosterone.

While often thought of as a “male” hormone, testosterone is the most abundant hormone in a woman’s body—women have approximately ten times more testosterone than estradiol. It is crucial not just for libido, but also for brain function, cognitive performance, motivation, energy, and muscle mass. Testosterone levels begin to decline in a woman’s 30s and plummet during perimenopause and menopause.

3. The Testosterone-Libido Connection

The link between testosterone and sexual desire in women is complex and a topic of intense clinical and research interest. Low libido is a common complaint among perimenopausal and postmenopausal women, and for many, testosterone therapy may offer a solution.

HSDD and the Evidence for Testosterone

Hypoactive Sexual Desire Disorder (HSDD) is characterized by a persistent or recurrent lack of sexual fantasies and desire for sexual activity that causes marked distress. Research demonstrates that testosterone treatment can be modestly beneficial in treating appropriately selected postmenopausal women with distressing low desire, also known as HSDD. In fact, the only evidence-based, guideline-supported use for testosterone in women is for the treatment of HSDD in postmenopausal women.

However, there are significant caveats. Firstly, no U.S. FDA-approved formulation of testosterone is currently available for women due to a lack of long-term safety data. Secondly, current data does not support the use of testosterone for bone health, brain health, or improving energy or cognition in women. The benefit of testosterone for women appears to be specific to addressing distressing low sexual desire. Despite this, two clinical guidelines now provide expert guidance on testosterone treatment and monitoring in women for HSDD.

The “Conundrum”: Libido Highs and Hair Loss Lows

The use of testosterone in women is not without its challenges. As one clinician describes it, there is a “conundrum”: testosterone therapy can boost libido but may also cause side effects like hair thinning in some women. This is because androgens like testosterone and DHT (dihydrotestosterone) enhance libido through increased dopamine, but DHT is also a key driver of hair loss.

A woman’s sensitivity to androgens significantly influences her response to therapy. Managing side effects often involves a delicate balance of dosing, choosing the right delivery method (e.g., creams versus injections), and potentially using 5-alpha-reductase inhibitors to manage DHT levels. Genetic predisposition, stress, and ferritin levels (iron stores) also play a significant role in hair health and loss. This underscores the need for comprehensive medical oversight and personalized treatment plans.

4. Peptide Therapy: The New Frontier

Peptides are short chains of amino acids that function as signaling molecules in the body, influencing a wide range of processes from tissue repair to hormone secretion. While interest in peptides for women’s health is surging, it is crucial to distinguish between promising preclinical evidence and validated clinical practice. Dr. Sarah Bonza, a board-certified family physician and Menopause Society Certified Practitioner, captures this nuance well: peptides should not be considered a “magic solution” or a replacement for foundational health.

BPC-157: The Healing Peptide

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in human gastric juice. Preclinical studies, primarily in animals, have demonstrated its potential to accelerate the healing of tendons, ligaments, muscles, and gastrointestinal tissue, with no reported toxicity in animal models.

For perimenopausal women, the theoretical applications include supporting recovery from exercise, addressing joint issues, and supporting gut health. However, the critical caveat is that BPC-157 has extremely limited human data, and the FDA has classified it as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmacies due to insufficient evidence of human safety. The World Anti-Doping Agency (WADA) has also banned it, and there are theoretical concerns about its pro-angiogenic (blood vessel-forming) properties potentially promoting tumor growth. BPC-157 is often combined with TB-500 as the “Wolverine stack” for its purported healing benefits.

TB-500: The Regenerative Peptide

TB-500 is a synthetic version of the active region of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue regeneration. Research suggests it may play a role in wound healing and reducing inflammation. TB-500 is often paired with BPC-157 to support recovery and reduce systemic inflammation.

However, TB-500 carries perhaps the most concerning cancer-related data of the peptides commonly discussed. Research shows that thymosin beta-4 is overexpressed in various human cancers and has been shown to stimulate tumor growth and metastasis. Like BPC-157, it is not FDA-approved and is banned by WADA.

GHK-Cu: The Copper Peptide for Skin and Tissue

GHK-Cu is a naturally occurring tripeptide that declines with age. Of the peptides discussed, it has perhaps the most robust human evidence, though still limited. A clinical trial published in the Journal of Aging Science demonstrated that topical GHK-Cu applied twice daily for 8 weeks reduced wrinkle volume by 55.8% and depth by 32.8%. It appears to stimulate collagen and elastin production and has antioxidant effects. While topical GHK-Cu appears relatively safe, injectable forms carry greater uncertainty and lack long-term safety data.

CJC-1295 & Ipamorelin: Growth Hormone Secretagogues

These peptides are often used in combination. CJC-1295 stimulates sustained growth hormone release, while ipamorelin produces a more immediate effect. For perimenopausal women experiencing declining growth hormone levels, this combination theoretically supports improved body composition, recovery, and sleep.

This is, however, where concerns become most significant. The increase in IGF-1 (insulin-like growth factor-1) that results from growth hormone stimulation is well-documented to be associated with an increased risk of various cancers, including breast, colorectal, and prostate cancers. One clinical trial of CJC-1295 was discontinued following a participant’s death, though the attending physician believed the event was unrelated to treatment. Neither peptide is FDA-approved, and the lack of long-term safety data makes them a high-risk proposition, especially for women with a personal or family history of hormone-sensitive cancers.

Collagen Peptides for Genitourinary Health

Genitourinary Syndrome of Menopause (GSM) encompasses symptoms like vaginal dryness, painful intercourse, urinary incontinence, and recurrent UTIs. While vaginal estrogen is the frontline treatment, researchers are exploring non-hormonal options. A clinical study is currently underway examining the impact of an oral supplement containing 2.5 grams of bioactive collagen peptides (BCP®) and other functional ingredients in menopausal women with GSM.

The study aims to evaluate improvements in quality of life and sexual function using validated questionnaires like the Female Sexual Function Index (FSFI). The hypothesis is that collagen peptides, which have shown beneficial properties in other tissues, may support the health of genitourinary tissues.

ProGo®: Salmon Protein Hydrolysate for Metabolic Health

Beyond reproductive health, weight gain is a common complaint in menopause. A salmon protein hydrolysate called ProGo® has shown promise in this area. Prior human studies have demonstrated moderate weight loss of 6%–7% with ProGo supplementation, likely due to improved energy levels, reduced inflammation, and improved metabolic health.

A randomized, placebo-controlled trial is currently evaluating ProGo for its effects on BMI and menopause-specific quality of life in overweight menopausal women. The study is examining two daily doses (2.0g and 4.0g) against a placebo over 18 weeks, with secondary outcomes including skin health, sleep, and vasomotor symptoms. This represents an exciting area of research into nutritional interventions that support metabolic health during the menopausal transition.

Oral Peptides for Bone Health (EB613)

Osteoporosis is a major concern for postmenopausal women, with studies showing that up to 20–24% of hip fracture patients die within one year of the fracture. Injectable anabolic (bone-building) drugs like teriparatide (Forteo®) are effective, but many women are reluctant to use daily injections.

A new oral peptide, EB613 (oral PTH(1-34)), is being developed as a once-daily tablet to address this gap. A Phase 2 study in postmenopausal women showed statistically significant increases in BMD at the lumbar spine, total hip, and femoral neck, comparable to the injectable version. The FDA has provided positive feedback on a Phase 3 registrational protocol for EB613, with the goal of making anabolic treatment more accessible to the millions of women at risk for osteoporotic fractures. Another injectable peptide for osteoporosis, Tymlos (abaloparatide), is already FDA-approved for postmenopausal women with osteoporosis at high risk for fracture.

5. The Foundation First: A Cautious, Evidence-Based Approach

One of the most important principles in functional and integrative medicine is that peptides and other novel therapies should not be used as a first-line treatment or as a replacement for foundational health. As Dr. Bonza emphasizes, before even considering peptides, the following must be addressed:

1. Hormonal Optimization: HRT (estrogen, progesterone, testosterone as indicated) should be optimized first. This addresses the root hormonal imbalance rather than just managing downstream symptoms.
2. Nutritional Replenishment: Correcting deficiencies in iron, vitamin D, B12, and magnesium is essential for metabolic function.
3. Nervous System Regulation: Addressing chronic stress, HPA axis dysregulation, and sleep quality is critical. Low libido is not always a hormone issue—chronic stress can leave women feeling emotionally numb and disconnected from their bodies.
4. Lifestyle Foundations: Consistent strength training, 7–8 hours of quality sleep, adequate protein intake, and sustainable stress management practices are non-negotiable.

Peptides, when appropriate, may enhance the gains from these foundational practices—not replace the work required to achieve them.

6. FAQ Section

7. References and Further Reading

1. Ben Greenfield. (2025). Balance Hormones, Boost Sex Life: Tips for Women’s Health.
2. ICHGCP. (2025). Étude sur les Compléments Oraux de Collagène pour la Santé Vaginale et Urinaire Ménopausique.
3. Kling, J.M. (2025). Testosterone for the Treatment of Hypoactive Sexual Desire Disorder in Perimenopausal and Postmenopausal Women. PubMed (NIH).
4. The Re/ Clinic. (2025). Why Women Are Talking About Wolverine Blend Peptide?
5. GlobeNewswire. (2026). Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613.
6. Apple Podcasts. (2026). Quick Hits: The Testosterone Replacement for Women Conundrum.
7. MedPath Trial. (2025). Impact of Oral Supplementation With Bioactive Collagen Peptides…
8. Kling, J.M. (2025). Testosterone for the Treatment of Hypoactive Sexual Desire Disorder… Obstetrics & Gynecology.
9. Modernaestheticsmd. (2025). Heal, Restore, and Optimize: BPC-157 / TB-500 / KPV Therapy for Women.
10. Drugs.com. (2022). Tymlos (abaloparatide) FDA Approval History.
11. The Balanced Body Podcast. (2026). Episode on Low Libido and Nervous System Health.
12. ICHGCP. (2026). ProGo Menopause Wellbeing Study.
13. GPnotebook. (2025). HRT assessment of risks and benefits based on age.
14. Bonza, S. (2025). Peptides in Perimenopause: A Physician’s Cautiously Curious Perspective. bonza health.